Upstream Bio (UPB) Preferred Stock Liabilities (2023 - 2024)
Upstream Bio (UPB) recorded quarterly Preferred Stock Liabilities of $380.9 million in Q3 2024, little changed quarter-over-quarter from $380.9 million in Q2 2024, and up 64.93% on a YoY basis from $230.9 million in Q4 2023.
Upstream Bio (UPB) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Upstream Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $380.9 million for Q3 2024.
- In Q3 2024, Preferred Stock Liabilities rose 64.93% year-over-year to $380.9 million; the TTM figure through Sep 2024 stood at $380.9 million (up 64.93% YoY), while the FY2023 annual figure was $230.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $380.9 million for Q3 2024 at Upstream Bio, roughly flat from $380.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $380.9 million in Q2 2024 to a low of $230.9 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 380.87 Mn |
| Jun 30, 2024 | 380.87 Mn |
| Mar 31, 2024 | 230.94 Mn |
| Dec 31, 2023 | 230.94 Mn |
| Sep 30, 2023 | 230.94 Mn |